461 related articles for article (PubMed ID: 25106415)
1. Clinical CYP3A inhibitor alternatives to ketoconazole, clarithromycin and itraconazole, are not transported into the liver by hepatic organic anion transporting polypeptides and organic cation transporter 1.
Higgins JW; Ke AB; Zamek-Gliszczynski MJ
Drug Metab Dispos; 2014 Nov; 42(11):1780-4. PubMed ID: 25106415
[TBL] [Abstract][Full Text] [Related]
2. Utility of Oatp1a/1b-knockout and OATP1B1/3-humanized mice in the study of OATP-mediated pharmacokinetics and tissue distribution: case studies with pravastatin, atorvastatin, simvastatin, and carboxydichlorofluorescein.
Higgins JW; Bao JQ; Ke AB; Manro JR; Fallon JK; Smith PC; Zamek-Gliszczynski MJ
Drug Metab Dispos; 2014 Jan; 42(1):182-92. PubMed ID: 24194513
[TBL] [Abstract][Full Text] [Related]
3. Interaction of oral antidiabetic drugs with hepatic uptake transporters: focus on organic anion transporting polypeptides and organic cation transporter 1.
Bachmakov I; Glaeser H; Fromm MF; König J
Diabetes; 2008 Jun; 57(6):1463-9. PubMed ID: 18314419
[TBL] [Abstract][Full Text] [Related]
4. In vivo disposition of doxorubicin is affected by mouse Oatp1a/1b and human OATP1A/1B transporters.
Durmus S; Naik J; Buil L; Wagenaar E; van Tellingen O; Schinkel AH
Int J Cancer; 2014 Oct; 135(7):1700-10. PubMed ID: 24554572
[TBL] [Abstract][Full Text] [Related]
5. Differential effects of Rifampin and Ketoconazole on the blood and liver concentration of atorvastatin in wild-type and Cyp3a and Oatp1a/b knockout mice.
Chang JH; Ly J; Plise E; Zhang X; Messick K; Wright M; Cheong J
Drug Metab Dispos; 2014 Jun; 42(6):1067-73. PubMed ID: 24671957
[TBL] [Abstract][Full Text] [Related]
6. Evaluation of Ketoconazole and Its Alternative Clinical CYP3A4/5 Inhibitors as Inhibitors of Drug Transporters: The In Vitro Effects of Ketoconazole, Ritonavir, Clarithromycin, and Itraconazole on 13 Clinically-Relevant Drug Transporters.
Vermeer LM; Isringhausen CD; Ogilvie BW; Buckley DB
Drug Metab Dispos; 2016 Mar; 44(3):453-9. PubMed ID: 26668209
[TBL] [Abstract][Full Text] [Related]
7. OATP1B3 Expression and Function is Modulated by Coexpression with OCT1, OATP1B1, and NTCP.
Zhang Y; Ruggiero M; Hagenbuch B
Drug Metab Dispos; 2020 Aug; 48(8):622-630. PubMed ID: 32482756
[TBL] [Abstract][Full Text] [Related]
8. Inhibition of hepatic uptake transporters by flavonoids.
Mandery K; Balk B; Bujok K; Schmidt I; Fromm MF; Glaeser H
Eur J Pharm Sci; 2012 May; 46(1-2):79-85. PubMed ID: 22394605
[TBL] [Abstract][Full Text] [Related]
9. Preclinical Mouse Models To Study Human OATP1B1- and OATP1B3-Mediated Drug-Drug Interactions in Vivo.
Durmus S; Lozano-Mena G; van Esch A; Wagenaar E; van Tellingen O; Schinkel AH
Mol Pharm; 2015 Dec; 12(12):4259-69. PubMed ID: 26474710
[TBL] [Abstract][Full Text] [Related]
10. Comparison of Hepatic Transporter Tissue Expression in Rodents and Interspecies Hepatic OCT1 Activity.
Morse BL; Fallon JK; Kolur A; Hogan AT; Smith PC; Hillgren KM
AAPS J; 2021 Apr; 23(3):58. PubMed ID: 33903987
[TBL] [Abstract][Full Text] [Related]
11. Inhibitory Effects of Green Tea and (-)-Epigallocatechin Gallate on Transport by OATP1B1, OATP1B3, OCT1, OCT2, MATE1, MATE2-K and P-Glycoprotein.
Knop J; Misaka S; Singer K; Hoier E; Müller F; Glaeser H; König J; Fromm MF
PLoS One; 2015; 10(10):e0139370. PubMed ID: 26426900
[TBL] [Abstract][Full Text] [Related]
12. Quantitative Analyses of the Influence of Parameters Governing Rate-Determining Process of Hepatic Elimination of Drugs on the Magnitudes of Drug-Drug Interactions via Hepatic OATPs and CYP3A Using Physiologically Based Pharmacokinetic Models.
Yoshikado T; Maeda K; Kusuhara H; Furihata KI; Sugiyama Y
J Pharm Sci; 2017 Sep; 106(9):2739-2750. PubMed ID: 28495568
[TBL] [Abstract][Full Text] [Related]
13. Determination of OATP-, NTCP- and OCT-mediated substrate uptake activities in individual and pooled batches of cryopreserved human hepatocytes.
De Bruyn T; Ye ZW; Peeters A; Sahi J; Baes M; Augustijns PF; Annaert PP
Eur J Pharm Sci; 2011 Jul; 43(4):297-307. PubMed ID: 21605667
[TBL] [Abstract][Full Text] [Related]
14. In vitro assessment of drug-drug interaction potential of boceprevir associated with drug metabolizing enzymes and transporters.
Chu X; Cai X; Cui D; Tang C; Ghosal A; Chan G; Green MD; Kuo Y; Liang Y; Maciolek CM; Palamanda J; Evers R; Prueksaritanont T
Drug Metab Dispos; 2013 Mar; 41(3):668-81. PubMed ID: 23293300
[TBL] [Abstract][Full Text] [Related]
15. Involvement of organic anion-transporting polypeptides and organic cation transporter in the hepatic uptake of jatrorrhizine.
Liang RF; Ge WJ; Song XM; Zhang JP; Cui WF; Zhang SF; Li GS
Xenobiotica; 2020 Apr; 50(4):479-487. PubMed ID: 31368836
[TBL] [Abstract][Full Text] [Related]
16. Human OATP1B1, OATP1B3 and OATP1A2 can mediate the in vivo uptake and clearance of docetaxel.
Iusuf D; Hendrikx JJ; van Esch A; van de Steeg E; Wagenaar E; Rosing H; Beijnen JH; Schinkel AH
Int J Cancer; 2015 Jan; 136(1):225-33. PubMed ID: 24825069
[TBL] [Abstract][Full Text] [Related]
17. Interactions of crizotinib and gefitinib with organic anion-transporting polypeptides (OATP)1B1, OATP1B3 and OATP2B1: gefitinib shows contradictory interaction with OATP1B3.
Sato T; Ito H; Hirata A; Abe T; Mano N; Yamaguchi H
Xenobiotica; 2018 Jan; 48(1):73-78. PubMed ID: 28005438
[TBL] [Abstract][Full Text] [Related]
18. The Nonmetabolized β-Blocker Nadolol Is a Substrate of OCT1, OCT2, MATE1, MATE2-K, and P-Glycoprotein, but Not of OATP1B1 and OATP1B3.
Misaka S; Knop J; Singer K; Hoier E; Keiser M; Müller F; Glaeser H; König J; Fromm MF
Mol Pharm; 2016 Feb; 13(2):512-9. PubMed ID: 26702643
[TBL] [Abstract][Full Text] [Related]
19. Organic anion transporting polypeptides and organic cation transporter 1 contribute to the cellular uptake of the flavonoid quercetin.
Glaeser H; Bujok K; Schmidt I; Fromm MF; Mandery K
Naunyn Schmiedebergs Arch Pharmacol; 2014 Sep; 387(9):883-91. PubMed ID: 24947867
[TBL] [Abstract][Full Text] [Related]
20. Murine Oatp1a/1b uptake transporters control rosuvastatin systemic exposure without affecting its apparent liver exposure.
Iusuf D; van Esch A; Hobbs M; Taylor M; Kenworthy KE; van de Steeg E; Wagenaar E; Schinkel AH
Mol Pharmacol; 2013 May; 83(5):919-29. PubMed ID: 23429889
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
